113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax®) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC)
2007 ◽
Vol 3
(3)
◽
pp. 148-155
2005 ◽
Vol 23
(16_suppl)
◽
pp. 4614-4614
2007 ◽
Vol 13
(13)
◽
pp. 3883-3891
◽
2015 ◽
Vol 3
(4)
◽
pp. 865-868
◽
2013 ◽
Vol 31
(3)
◽
pp. 177-182
◽
1994 ◽
Vol 16
(3)
◽
pp. 224-228
◽
2001 ◽
Vol 85
(10)
◽
pp. 1467-1471
◽